A shadow market for GLP-1 weight-loss drugs has emerged online, where compounded semaglutide and tirzepatide and “for research only” peptide powders are sold without prescriptions, driving a surge in poison control calls and raising supply-chain and safety questions for the peptide therapy industry. The U.S. Food and Drug Administration (FDA) removed semaglutide from its drug shortage list in February 2025 and tirzepatide in October 2024, setting the stage for compounded versions to be phased out by May 2025, pending litigation, according to reporting by Science News.
For peptide therapy clinics, telehealth platforms, compounding pharmacies and research peptide suppliers, the shift marks a critical test: patients who relied on compounded GLP-1 drugs may migrate to unregulated online sources, including lyophilized “research-only” vials that require self-reconstitution and injection. This article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
What Happened: From Shortage to Shadow Market
Ozempic and Wegovy, both made by Novo Nordisk, had been on the FDA’s drug shortage list since 2022. During that period, compounding pharmacies legally produced copies of semaglutide to fill supply gaps. But as early as late 2022, Joseph Lambson, a pharmacist and board-certified toxicologist, received a call from a poison control specialist about patients injecting 10 times the correct dose of semaglutide. Lambson’s team at the Utah Poison Control Center in Salt Lake City later reported that people were overdosing on compounded semaglutide, experiencing nausea, vomiting and diarrhea.
The problem persisted. Last year in Clinical Toxicology, emergency medicine doctors reported a case in which a man injected 20 times the correct dose because he misunderstood instructions. The FDA’s removal of semaglutide and tirzepatide from the shortage list means pharmacies will no longer be able to dispense compounded versions by May 2025, though ongoing litigation could alter that timeline.
Key Numbers: Poison Control Calls and Adverse Event Reports
According to America’s Poison Centers, U.S. poison control centers managed 8,502 GLP-1-related cases in 2024, compared with 892 in 2019, an 850% increase. About 75% of those cases were unintentional therapeutic errors, meaning people used the wrong dose or administered the drug incorrectly, according to Kaitlyn Brown of America’s Poison Centers. In New Mexico, GLP-1-related calls have doubled every year since 2021, according to Lambson, now director of the state’s Poison and Drug Information Center.
The FDA has received nearly 800 reports of adverse events linked to compounded semaglutide or tirzepatide as of February 28, 2025. Meanwhile, a study of nearly 216,000 U.S. veterans published in January in Nature Medicine found that people on GLP-1 drugs were less likely to have substance use disorders, psychotic disorders, seizures, dementia and infections. A separate study in January in JAMA Network Open found that 65% of people without type 2 diabetes who take a GLP-1 drug quit within a year. And research in April in the Annals of Internal Medicine estimated fewer than four emergency department visits per 1,000 patients dispensed semaglutide.
| Metric | Value | Source |
|---|---|---|
| GLP-1-related poison control cases, 2024 | 8,502 | America’s Poison Centers |
| GLP-1-related poison control cases, 2019 | 892 | America’s Poison Centers |
| Increase in cases, 2019–2024 | 850% | America’s Poison Centers |
| Share of cases due to unintentional therapeutic errors | ~75% | Kaitlyn Brown, America’s Poison Centers |
| FDA adverse event reports linked to compounded semaglutide or tirzepatide (as of Feb 28, 2025) | Nearly 800 | FDA |
| Discontinuation rate within one year (without type 2 diabetes) | 65% | JAMA Network Open, January 2025 |
Why It Matters for Peptide Therapy and Research Peptides
The end of legal compounding for semaglutide and tirzepatide does not eliminate demand. Patients who used compounded versions may seek cheaper alternatives online, where vendors sell GLP-1 drugs “for research only” as powdered semaglutide or tirzepatide to anyone with a credit card and without a prescription. These products typically require buyers to reconstitute and inject themselves, without physician guidance. Scientists around the country have raised concerns about drug quality, dosing and scams.
For peptide therapy clinics and telehealth operators, the shift raises questions about patient counseling and continuity of care. C. Michael White, a pharmacist, told Science News he worries that people reliant on legitimate compounded products may soon “go further down the rabbit hole.” Tim Mackey, a researcher, said, “Everyone’s trying to make money — manufacturers, compounding pharmacies, counterfeiters, everybody… I really think the patient is the victim here.”
PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates.
Research and Market Context: Quality, Supply Chain and Regulation
The FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed, according to the agency. For research peptides, a certificate of analysis (COA) reports specified analytical results for a batch but does not independently establish clinical safety, efficacy, sterility for a particular use, regulatory approval, or suitability for administration to humans. Chromatographic purity, such as an HPLC area percentage, may not account for water, counterions, residual solvents or components with different detector responses; a suitable quantitative assay is needed to establish content.
In the supply chain, the distinction between a peptide API and a finished drug product is critical. A peptide API is the active pharmaceutical ingredient used in drug manufacturing; a finished drug product combines the active ingredient with appropriate formulation, container closure, manufacturing controls, labeling and release requirements. API quality alone does not establish finished-product quality or regulatory approval. For clinics and research businesses evaluating suppliers, documented identity, batch-specific analytical data, impurity characterization, manufacturing transparency and traceability are essential.
Packaging and device choices also matter. Lyophilized powders for vials or dual-chamber cartridges require reconstitution, while prefilled injection pens are designed to reduce dosing errors. The FDA’s shortage-list decisions do not change the underlying need for proper container closure integrity, material compatibility and stability data for any peptide product.
What Comes Next: Litigation, Enforcement and Patient Behavior
The timing of the compounding phase-out depends on ongoing litigation. If courts allow the FDA’s timeline to stand, compounded semaglutide and tirzepatide will become unavailable through pharmacies by May 2025, potentially pushing some patients toward unregulated online sources. How many patients will make that shift, and what quality and safety risks they will face, remain unknown. The available evidence does not yet establish the extent to which the “research-only” market is causing adverse events.
For industry participants, the key watch items are FDA enforcement actions, court rulings, state pharmacy board guidance and the volume of adverse event reports linked to compounded or research-only GLP-1 products. Clinics and telehealth platforms may need to strengthen patient education on dosing and sourcing, while research peptide suppliers face renewed scrutiny over labeling and marketing claims.
多肽供应链资源网 as a provider in the industry domain, PeptideSCM tracks these supply-chain and regulatory developments for peptide professionals.
Frequently Asked Questions
What is compounded semaglutide?
Compounded semaglutide is a copy of the active ingredient in Ozempic and Wegovy, prepared by a compounding pharmacy, typically during a drug shortage. It is not FDA-approved as a compounded product, and the FDA does not review compounded drugs for safety, effectiveness or quality before marketing.
Why did poison control calls increase?
Poison control centers managed 8,502 GLP-1-related cases in 2024, up 850% from 892 in 2019. About 75% were unintentional therapeutic errors, often involving incorrect dosing of compounded semaglutide that required patients to draw doses with a syringe.
What does “for research only” mean for GLP-1 peptides?
“For research use only” indicates a stated research purpose rather than authorization for clinical treatment. It does not verify product quality or establish that the material is safe or effective for human use. Buyers should not assume research-only GLP-1 powders are equivalent to approved medicines.
Will compounded GLP-1 drugs still be available after May 2025?
The FDA removed semaglutide from the shortage list in February 2025 and tirzepatide in October 2024. By May 2025, pharmacies will no longer be able to dispense compounded versions, though that depends on ongoing litigation.
How can clinics verify a peptide supplier?
Clinics should request batch-specific COAs, product specifications, analytical method information, impurity profiles, stability data and manufacturing-site information. They should also confirm the supplier’s traceability and quality-system documentation, and verify regulatory status for the specific product and indication.
Comments